Episodes

In this episode of PayerTalkCE®, we will delve into the innovations around HER2-targeting therapies and their role in the treatment of select gastrointestinal cancers. Topics will include the latest evidence and the integration of new treatments into health care systems, insurance coverage, reimbursement challenges, and the overall impact on health care policy. This activity is certified for CME/CNE/CPE credit. To participate and earn credit, visit us at https://www.impactedu.net/gi-cancer-manag...

In this episode of PayerTalkCE® we will explore the epidemiology and burdens of gastroesophageal and biliary tract cancers. Experts will discuss the importance of early and accurate diagnosis in managing treatment efficacy and cost. The episode will also delve into the role of personalized medicine and multidisciplinary approaches and provide collaborative and actionable insights on how managed care professionals can adapt their strategies to better accommodate the complexities associated with r...

This podcast explores macular telangiectasia (MacTel), a rare and progressive retinal disease, with a focus on advancing early detection, appropriate treatment, and health system coordination. Retina specialist Dr. Jay Chhablani discusses the shift in understanding MacTel as a neurodegenerative—not vascular—condition, highlighting the limitations of anti-VEGF therapy and the significance of a newly approved, durable implant that targets neuroprotection. The discussion outlines the importance of ...

This podcast highlights opportunities for managed care organizations to improve COPD management by aligning coverage policies with current clinical evidence and treatment guidelines. Experts discuss new therapies, including recently approved biologics and inhaled agents, and their roles in treating patients with frequent exacerbations or type 2 inflammation. The session also addresses implementation barriers such as limited spirometry access, inconsistent pulmonary rehab availability, and dispar...

This podcast features expert discussion on the emerging role of type 2 (T2) inflammation in chronic obstructive pulmonary disease (COPD) and the implications for payer and provider decision-making. Faculty review key pathophysiologic mechanisms and biomarkers—particularly eosinophil counts—that identify patients most likely to benefit from targeted biologic therapies. The conversation also explores updated GOLD guideline recommendations, strategies to optimize formulary access, the impact of T2 ...

This podcast reviews a case-based discussion on managing age-related macular degeneration (AMD), a leading cause of blindness among older adults, particularly those enrolled in Medicare Advantage plans. Experts review the progression of AMD, key diagnostic tools, and the importance of timely anti-VEGF therapy to prevent vision loss. The conversation highlights payer considerations, including step therapy requirements, treatment burden, and long-term cost implications. It also addresses challenge...

This podcast explores the challenges of managing diabetic retinopathy in patients with type 1 diabetes, focusing on a case study of a working-age patient with barriers to care. Expert insights highlight the importance of early screening, timely intervention, and payer strategies to facilitate access to specialty care. Discussion covers diagnostic approaches, treatment selection, and the role of anti-VEGF therapies, including considerations around step therapy and treatment adherence. The convers...

This podcast provides health plan professionals with expert insights on best practices for managing moderate to severe asthma, focusing on type 2 inflammation. Discussion topics include current treatment guidelines, the role of biomarkers in therapy selection, and the impact of biologics on reducing exacerbations and healthcare utilization. Experts also examine challenges in asthma management, such as adherence barriers, care fragmentation, and affordability, while highlighting opportunities for...

This podcast provides health plan professionals with an in-depth discussion on the role of type 2 (T2) inflammation in asthma pathophysiology and the evolving treatment landscape. Experts explore the mechanisms driving T2 inflammation and how biomarkers can help guide therapy selection. The conversation highlights biologic treatments' clinical and economic considerations, including their impact on reducing exacerbations, optimizing outcomes, and managing healthcare costs. Panelists also discuss ...

This podcast explores payer best practices in managing atopic dermatitis, emphasizing the role of type 2 inflammation and its impact on patient outcomes. Experts discuss current treatment guidelines, the efficacy of emerging therapies, and strategies for tailoring care to patient needs, including those with darker skin tones. Key barriers such as access to dermatologists, treatment complexity, and psychosocial impacts are highlighted, with insights on payer strategies to improve access and affor...

This podcast provides an in-depth exploration of type 2 inflammation and its role in the pathophysiology and management of atopic dermatitis, tailored for health plan professionals. Experts discuss the molecular mechanisms driving the condition, including key cytokines like IL-4 and IL-13, and highlight the clinical and quality-of-life impacts for patients. The conversation covers the evolution of targeted therapies, including biologics and JAK inhibitors, and emphasizes the importance of shared...